The Meng lab focuses on design and characterization of inspired drug delivery systems for the purpose of modulating immune functions.  The group pursues projects that bridge gaps between preclinical and clinical stages in drug development, focusing on enhancing drug bioavailability in target tissues while reducing systemic toxicities.  The main thrust of the lab is to repurpose biologics for locoregional immunomodulation.

Current research themes include:  Design and characterize bioaffinity hydrogels for delivering antibodies and other recombinant proteins; synthesis and optimization of surface-functionalized nanoparticles for delivering protein antigens and small molecules and, develop and apply unique bioinformatics approaches to predict T cell epitopes.

View a list of Dr. Meng’s publications here.

Wilson Meng graduated from the University of Maryland School of Pharmacy and practiced pharmacy in Maryland and California.  He received his PhD in Pharmaceutical Sciences from the University of Southern California.  After completing a postdoctoral fellowship at the UCLA School of Medicine, he joined Duquesne University, where he is currently Professor of Pharmaceutics.  He was a visiting scientist at the Molecular Biosensor and Imaging Center at Carnegie Mellon University.  He has served as grant reviewer for the National Institutes of Health (P01, U19, regular study sections and fellowships) and the Department of Defense (PRMRP and KCRP).  He is an associate editor for the Journal of Pharmaceutical Innovation (Springer/Nature) and has served as guest editor for Clinical Immunology (Elsevier).